The HTA Coordination Group (HTACG) has now confirmed the 2026 request periods for joint scientific consultations – and it’s time to start planning your pipeline strategy.
Request periods for Joint Scientific Consultation in 2026
- 07 January – 04 February 2026
- 01 – 29 April 2026
- 03 June – 01 July 2026
- 23 September – 21 October 2026
Consultation slots in the first two request periods
Request period 1: 07 January – 04 February 2026
Available slots (briefing document due by):
- 07 April 2026
- 04 May 2026
- 08 June 2026
Request period 2: 01 – 29 April 2026
Available slots (briefing document due by):
- 06 July 2026
- 31 August 2026
- 28 September 2026
Slots for the later request periods (June–July and September–October) will be announced in due course.
What to expect in 2026
HTACG anticipates next year:
- ~50 Joint Clinical Assessments (JCAs) on medicinal products
- ~5 JCAs on medical devices
- 8–12 Joint Scientific Consultations on medicinal products
- 2–5 Joint Scientific Consultations on medical devices
With limited JSC slots and a growing number of products in scope, early planning will be critical to:
- Align your development programme with future EU HTA evidence expectations
- Secure an appropriate consultation slot for your asset
- Prepare a high-quality briefing book that addresses the needs of multiple HTA bodies
How Remap Consulting can help
As a specialist pricing and market access consultancy, Remap Consulting supports pharma and medtech companies to:
- Prioritise which assets should go into JSC
- Develop robust briefing documents and value-focused questions
- Optimise clinical and evidence generation plans in light of upcoming JCAs
If you’re considering a joint scientific consultation in 2026, now is the time to start the conversation.
👉 Get in touch with the Remap Consulting team to discuss how these timelines impact your portfolio and how we can support you. Contact us here